VR Logo

Adaptive Biotechnologies Corporation (ADPT) download report


Healthcare | Biotechnology & Pharma Research

Adaptive Biotechnologies Corporation (ADPT) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.

IPO Date: 27-Jun-2019

Co-Founder, CEO & Chairman: Mr. Chad M. Robins M.B.A, M.B.A.

Pres: Ms. Julie Rubinstein

Listing: NASDAQ: ADPT

Country: United States

Headquarters: Seattle, WA

Website: https://www.adaptivebiotech.com

Key Facts

Market cap: $1,197.56 Mln

Revenue (TTM): $154.52 Mln

Earnings (TTM): $-229.37 Mln

Cash: $363.56 Mln

Total Debt: $113.52 Mln

Insider's Holding: 1.67%

Liquidity: Low

52 Week range: $5.96 - 40.00

Shares outstanding: 142,228,000

5 Years Aggregate:

  • CFO: $-204.12 Mln
  • EBITDA: $-469.38 Mln
  • Net Profit: $-511.39 Mln

Stock Performance

Time Period Adaptive Biotechnologies (ADPT) S&P BSE Sensex S&P Small-Cap 600
YTD-68.64-8.79-19.61
1 month26.80-4.72-9.38
3 months-39.52-12.34-15.04
1 Year-77.611.24-17.73
3 Years-39.2010.015.82
5 Years--11.235.47
10 Years--11.779.50
As on 05-Jul-2022
Year Adaptive Biotechnologies (ADPT) S&P Small-Cap 600 S&P BSE Sensex
2021-52.5525.2721.99
202097.639.5715.75